From The Editor | September 26, 2016

Podcast: Pfizer Transforms Clinical Trials for Parkinson's Patients

Source: Clinical Leader
Ed Miseta

By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical


When Pfizer partnered with IBM to try and transform how clinical trials for Parkinson’s patients are conducted, the company had a vision that was both revolutionary and futuristic. The plan was to take a group of patients, place them in a specially designed home to live for a period of time, and use sensor technology to monitor their capabilities. For this edition of PHARMA talkRADIO, Valerie Bowling, executive director of The Conference Forum, and Ed Miseta, chief editor for Clinical Leader, brought together a team from Pfizer to discuss the initiative. That team included:

Daniel Karlin, senior director, quantitative medicine, Clinical Lead, BlueSky, Pfizer

David Caouette, senior director, strategy and operations lead, BlueSky and quantitative medicine, Pfizer

Stephen Amato, project manager, BlueSky, Pfizer

There are two ways to listen to this podcast. Click here if you would like to download it from iTunes. You may also stream it online by clicking here. The presentation is approximately 30 minutes.